Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

Código QR

Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

Abstract Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sheriza Baksh, Jiajun Wen, Omar Mansour, Hsien-Yen Chang, Mara McAdams-DeMarco, Jodi B. Segal, Stephan Ehrhardt, G. Caleb Alexander
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a638a7a3df1f45569c97db45d9e14c45
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
por: Das SS, et al.
Publicado: (2014)

Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts
por: Emilie Normand, et al.
Publicado: (2017)

Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis
por: Nehru Sai Suresh Chalichem, et al.
Publicado: (2021)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
por: Taehwan Park, et al.
Publicado: (2021)

Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.
por: Margaret G Gall, et al.
Publicado: (2013)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis
por: Yi-Chen Li, et al.
Publicado: (2021)

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
por: Gurgel Penaforte-Saboia J, et al.
Publicado: (2021)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
por: Aleksander Sergeevich Ametov, et al.
Publicado: (2015)

Molecular Dynamics Simulations Study of the Interactions between Human Dipeptidyl-Peptidase III and Two Substrates
por: Shitao Zhang, et al.
Publicado: (2021)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
por: Jorge Andrés Barrero, et al.
Publicado: (2021)

Dipeptidyl peptidase III as a DNA marker to investigate epidemiology and taxonomy of Old World Leishmania species.
por: Insaf Bel Hadj Ali, et al.
Publicado: (2021)

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
por: Galina Smushkin, et al.
Publicado: (2009)

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
por: Lana C. Pinto, et al.
Publicado: (2018)

Structural basis for an exceptionally strong preference for asparagine residue at the S2 subsite of Stenotrophomonas maltophilia dipeptidyl peptidase 7
por: Akihiro Nakamura, et al.
Publicado: (2021)

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
por: Suman RK, et al.
Publicado: (2016)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.
por: Soo Lim, et al.
Publicado: (2012)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
por: Gagik Radikovich Galstyan, et al.
Publicado: (2015)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
por: James M. Henderson, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
por: Ming Zhao, et al.
Publicado: (2017)

Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction
por: Jing Wei Li, et al.
Publicado: (2017)

The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
por: Nur Imanina Abdullah Thaidi, et al.
Publicado: (2020)

Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
por: Kornél Király, et al.
Publicado: (2018)

Association between renal function and cardiovascular mortality: a retrospective cohort study of elderly from health check-up
por: Ta-Chien Chan, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Sequential alcalase and flavourzyme treatment for preparation of α-amylase, α-glucosidase, and dipeptidyl peptidase (DPP)-IV inhibitory peptides from oat protein
por: Lourdes Ramírez Fuentes, et al.
Publicado: (2021)

Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19
por: Rhian M. Touyz, MBBCh, PhD, et al.
Publicado: (2021)

New Evidence of Renal and Cardiovascular Alterations Promoted by Bisphenol A
por: Rafael Moreno-Gómez-Toledano, et al.
Publicado: (2021)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
por: Hiroshi Kasamatsu, et al.
Publicado: (2021)

Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
por: Mattia Cattaneo, et al.
Publicado: (2019)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
por: Woodman OL, et al.
Publicado: (2019)

Blood Pressure and Cardiovascular Disease in Older Patients With Diabetes: Retrospective Cohort Study
por: Sangmo Hong, et al.
Publicado: (2021)

Cardiovascular risk evaluation in chronic renal patients in non-dialysis by anthropometric indicators
por: Adriana dos Santos Dutra, et al.
Publicado: (2021)

The emerging plasma biomarker Dickkopf-3 (DKK3) and its association with renal and cardiovascular disease in the general population
por: Arnold Piek, et al.
Publicado: (2021)

Cardiovascular pathology the official journal of the Society for Cardiovascular Pathology.
Publicado: (1992)

A review of cardiovascular and renal function monitoring: a consideration of older adults with HIV
por: Kebodeaux CD, et al.
Publicado: (2013)